摘要
目的探讨二甲双胍联合吉非替尼治疗非小细胞肺癌的临床疗效。方法选取医院2016年7月至2018年7月收治的非小细胞肺癌患者154例,采用双色球法随机分为对照组和联合组,各77例。两组患者均予吉非替尼片口服,联合组患者加服盐酸二甲双胍片。两组均治疗8周。结果联合组总有效率为96.10%,显著高于对照组的80.52%(P<0.05);治疗后,联合组患者的鳞状细胞癌抗原、细胞角蛋白19片段抗原21-1、基质金属蛋白酶-9水平均显著低于对照组,组织蛋白酶抑制剂-1水平显著高于对照组(P<0.05);联合组与对照组患者随访1年内的生存率相当(89.61%比84.42%,P>0.05),联合组患者的中位生存期显著长于对照组(P<0.05);两组患者的腹泻、皮疹、肝功能损害、肾功能损害等不良反应发生率相当(P>0.05)。结论二甲双胍联合吉非替尼治疗非小细胞肺癌效果显著,可明显降低患者血清肿瘤标志物及间质细胞相关蛋白表达水平,并能提高生存质量。
Objective To investigate the clinical efficacy of metformin combined with gefitinib in the treatment of patients with non-small cell lung cancer(NSCLC).Methods Totally 154 patients with NSCLC admitted to our hospital from July 2016 to July 2018 were selected and randomly divided into the control group and the combined group according to the double-color ball method,77 cases in each group.The patients in the two groups took Gefitinib Tablets orally,on this basis,the patients in the combined group took Metformin Hydrochloride Tablets orally.Both groups were treated for eight weeks.Results The total effective rate of the combined group was 96.10%,which was significantly higher than 80.52%of the control group(P<0.05).After treatment,the levels of squamous cell carcinoma antigen(SCCA),human cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)and matrix metalloproteinase-9(MMP-9)in the combined group were significantly lower than those in the control group(P<0.05),while the level of tissue inhibitor of metalloproteinases-1(TIMP-1)in the combined group was significantly higher than that in the control group(P<0.05).The 1-year survival rate of the combined group was similar to that of the control group(89.61%vs.84.42%,P>0.05).The median survival time of the combined group was significantly longer than that of the control group(P<0.05).The incidence of diarrhea,rash,liver function damage,renal function damage and other adverse reactions in the two groups was similar(P>0.05).Conclusion Metformin combined with gefitinib is effective in the treatment of NSCLC,it can significantly reduce the expression levels of serum tumor markers and interstitial cell-related proteins,and improve the quality of life.
作者
陈民彪
蔡仁中
黄修明
陈献珊
CHEN Minbiao;CAI Renzhong;HUANG Xiuming;CHEN Xianshan(Department of Thoracic Surgery,Halnan General Hospltal,Haikou,Hainan,China 570311)
出处
《中国药业》
CAS
2021年第4期38-40,共3页
China Pharmaceuticals
基金
海南省卫生计生行业科研项目[18A200050]。
关键词
二甲双胍
吉非替尼
非小细胞肺癌
间质细胞相关蛋白
肿瘤标志物
预后
临床疗效
metformin
gefitinib
non-small cell lung cancer
interstitial cell-related protein
tumor markers
prognosis
clinical efficacy
